| Name | Title | Contact Details |
|---|---|---|
Teri Minard |
Director of Government Sales | Profile |
Tri-therapy Inc is a Searcy, AR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Precept is a Arden, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PrinterPrezz`s mission is to bring more ideas for innovative medical devices to market faster, connecting medicine and manufacturing to become the first Medifacturing™ company in the world. By developing advanced medical devices using processes that combine expertise in 3D printing, orthopaedics, semiconductor and nanotechnologies, PrinterPrezz`s ultimate goal is to provide medical solutions that enable people to enjoy active lives longer. PrinterPrezz`s ecosystem aims to solve challenges for various parts of the medical innovation value chain by providing prototyping, development, and manufacturing services to create life-enhancing medical devices. Committed to ongoing compliance with ISO13485:2016 and all relevant regulatory requirements, PrinterPrezz provides customers with access to a variety of 3D printing machines, 3D manipulation software, and 3D scanners as well as advanced manufacturing processes, and surgeon education programs. Medical solutions created by PrinterPrezz are designed to enable more people to live happier and more gratifying lives.
Covalent Medical Inc is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe